Swiss drugs regulator approves Moderna's COVID-19 vaccine

Joe Biden receives second dose of coronavirus vaccine on camera

The vaccine comes with a "Made in Switzerland" label, as contract drug manufacturer Lonza makes its active ingredients at its factories in Visp, near the Matterhorn mountain.

German vaccination centers received the first doses of the Moderna vaccine on Tuesday, as health officials ramp up a vaccination campaign that has been criticized for its relatively slow start.

Pfizer, however, does not believe there is a connection between the vaccine and the death based on its clinical trials of the shot and its "post-marketing experience thus far", Pitts said.

The Moderna vaccine, like the Pfizer-BioNTech, is said to be about 95 percent effective as the government awaits for European Union approval of the United Kingdom's AstraZeneca vaccine that's only 70 percent effective.

"If we had plenty of vaccines, we would not be asking any questions", said Quach.

Both Moderna and Pfizer's vaccines require two doses, separated by about a month.

Asda is also supporting the NHS with its rollout of the Oxford/AstraZeneca vaccine, which is easier to transport and store, with the use of its 238 in-store pharmacies. The company is studying whether a second dose increases efficacy or durability of the immune response.

Canada's national panel of vaccine experts says the second COVID-19 vaccine dose can be delayed briefly in order to quickly get first doses to more people.

"And when you know you're going to get the vaccine the next day, try to get a good night's sleep".

The World Health Organization, Van Hoof said, points out that the ideal profile of a pandemic vaccine is different from one during normal times.

Another 2.7 million doses of the BioNTech-Pfizer vaccine are expected by mid-February, according to the Health Ministry.

Dr Carlo de Notaristefani, lead manufacturing adviser for Operation Warp Speed, acknowledged the delay to The Times. The drugmaker remains on track to hit the goal of producing 1 billion doses before year-end, Stoffels said in the interview.

"The Company anticipates announcing topline Phase 3 data for its single-dose Janssen COVID-19 vaccine candidate in late January 2021; however, as this trial is dependent on disease events, the timing is approximate", Johnson & Johnson said in a statement.

Related:

Comments


Other news